ROIV
Roivant Sciences Ltd.
Stock
$35.72+0.22 (+0.62%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | −$816M | −$750M | −$839M | −$765M | −$843M | −$678M | −$552M |
| Capital expenditures | — | $8.2M | $4.6M | $1.4M | $13M | $17M | $5.8M |
| Free cash flow | — | −$759M | −$844M | −$767M | −$856M | −$695M | −$558M |
| Stock-based compensation | $347M | $346M | $289M | $200M | $218M | $565M | $85M |
| Buybacks | — | — | $1.3B | $0 | $0 | — | — |
| Free cash flow margin | — | −9,183.5% | −2,905.2% | −2,343.6% | −2,715.1% | −1,257.4% | −2,344.8% |